Uveitis
MONDO:0020283An inflammatory process affecting a part of or the entire uvea. Causes include inflammatory agents (e.g., herpes simplex, herpes zoster, leptospirosis) and systemic diseases (e.g., inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis). Patients present with pain and redness in the eye, light sensitivity, and blurred and decreased vision.
Also known as: inflammation of uvea, uvea inflammation, uveitis, uveitis (disease)
62 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental antibody takes aim at eye inflammation
Disease control TerminatedThis study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 18, 2026 07:00 UTC
-
Eye infection breakthrough: new trial tests antivirals to save sight
Disease control TerminatedThis study compared two antiviral medicines (oral valganciclovir and topical ganciclovir 2%) against a placebo for treating CMV-related inflammation in the front of the eye. The goal was to see which approach better controls the infection and reduces complications like pain, glau…
Phase: PHASE2, PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused TerminatedThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC